Please try another search
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug; and STP1002, an anti-cancer drug. The company also provides healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and derma business areas; CDMO services; imaging equipment and ENT workstation products; mineral water under the Cheonnyeonsu brand name; and IT and construction services. In addition, it produces glass bottles, PET, and corrugated cardboard boxes; engages in the foundry equipment, logistics, and food and beverage businesses. The company was founded in 1932 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Shin-Ho Kang | 97 | - | Honorary Chairperson |
Kyoung Bae Kwon | - | 2021 | Independent Non-Executive Outside Chairman |
Young-Sam Keum | - | 2022 | Independent Outside Director |
Jae-Hun Jung | 53 | 2021 | CEO, VP & Inside Director |
Se-Won Kwon | - | 2022 | Independent Outside Director |
Seung Hyun Ko | - | 2021 | Executive Director, CFO & Head of Management Support Office |
Min-Woo Jo | - | 2023 | Executive Director & Head of Management Planning Office |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review